Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SGEN - Seagen Inc.

IEX Last Trade
194.64
0.990   0.509%

Share volume: 642,442
Last Updated: Tue 08 Aug 2023 09:59:53 PM CEST
Biological Product (except Diagnostic) Manufacturing : -4.32%

PREVIOUS CLOSE
CHG
CHG%
$193.65
0.99
0.51%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 25%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.98%
1 Month
1.12%
3 Months
-3.11%
6 Months
40.90%
1 Year
10.15%
2 Year
20.29%
Key data
Stock price
$194.64
P/E Ratio 
-50.12
DAY RANGE
N/A - N/A
EPS 
-$3.89
52 WEEK RANGE
$116.08 - $207.17
52 WEEK CHANGE
$0.09
MARKET CAP 
36.348 B
YIELD 
N/A
SHARES OUTSTANDING 
187.698 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.34
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$684,653
AVERAGE 30 VOLUME 
$1,015,639
Company detail
CEO: David R. Epstein
Region: US
Website: seagen.com
Employees: 3,260
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate, PADCEV, and TUKYSA. It also develops TIVDAK for metastatic cervical cancer and other solid tumors.

Recent news